A detailed history of Wells Fargo & Company transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 12,956 shares of LRMR stock, worth $80,715. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,956
Previous 13,469 3.81%
Holding current value
$80,715
Previous $97,000 13.4%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$6.3 - $10.68 $3,231 - $5,478
-513 Reduced 3.81%
12,956 $84,000
Q2 2024

Aug 13, 2024

BUY
$6.33 - $9.89 $25,579 - $39,965
4,041 Added 42.86%
13,469 $97,000
Q1 2024

May 10, 2024

BUY
$4.2 - $13.28 $6,018 - $19,030
1,433 Added 17.92%
9,428 $71,000
Q4 2023

Feb 09, 2024

BUY
$2.35 - $4.71 $3,677 - $7,371
1,565 Added 24.34%
7,995 $36,000
Q3 2023

Nov 13, 2023

SELL
$3.08 - $4.49 $10,364 - $15,108
-3,365 Reduced 34.35%
6,430 $25,000
Q2 2023

Aug 15, 2023

BUY
$3.13 - $5.27 $30,032 - $50,565
9,595 Added 4797.5%
9,795 $30,000
Q1 2023

May 12, 2023

BUY
$4.0 - $6.68 $12 - $20
3 Added 1.52%
200 $0
Q4 2022

Feb 13, 2023

BUY
$2.73 - $5.08 $270 - $502
99 Added 101.02%
197 $0
Q3 2022

Nov 14, 2022

BUY
$1.53 - $3.64 $30 - $72
20 Added 25.64%
98 $0
Q2 2022

Aug 12, 2022

BUY
$1.9 - $3.98 $148 - $310
78 New
78 $0
Q1 2021

May 13, 2021

SELL
$14.61 - $22.19 $81,874 - $124,352
-5,604 Closed
0 $0
Q4 2020

Feb 09, 2021

BUY
$14.28 - $25.06 $78,897 - $138,456
5,525 Added 6993.67%
5,604 $120,000
Q3 2020

Nov 05, 2020

BUY
$10.5 - $17.6 $661 - $1,108
63 Added 393.75%
79 $1,000
Q2 2020

Aug 13, 2020

BUY
$0.72 - $16.76 $11 - $268
16 New
16 $0

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $270M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.